Glaxo announces a $2.3 billion in legal liability charges

British pharmaceutical giant GlaxoSmithKline, announced this Thursday that its second-quarter charges related to legal cases involving the two drugs Avandia (diabetes drug) and Paxil (drug for anxiety and depression) would run up to $2.36 billion. Avandia’s use and its potential risk of causing heart problems were being debated this week by an advisory panel to the US Food & Drugs Administration (FDA).

While investors welcomed this announcement, stock analysts feel that the action taken by the FDA was better than expected and the $2.1 billion charge set a likely ceiling on the company’s legal liabilities. As a result the stocks also moved upwards late Wednesday after the advisory committee voted, and again Thursday after the announcement of the charge for legal issues. End of the day the stocks were up by 2.3 percent, to $37.21 in a market that declined slightly overall and rose slightly in most other pharmaceutical stocks. Since a low point on Wednesday afternoon before the FDA vote, GlaxoSmithKline’s stock has risen by nearly 5 percent. Shares rose 21.5 pence, or 1.8 percent, to £12.03 a share in London. Reported profits of the company were about $8.4 billion for 2009.

Avandia was the widest selling diabetes drug until reports appeared in 2007 that it was linked to increased risk of heart problems like heart attacks, heart failures and strokes and heart related deaths. Sales plummeted thereafter. In a 2007 advisory panel meeting the drug was given no health warnings. In the recent vote on Wednesday however the expert panel was skeptical about the complete safety of the drug. After the final vote and decision Avandia remains in the market but will be sold with a warning.

It was initially feared that Avandia lawsuits would cost the company around $6 billion. However on Thursday GSK spokesperson announced that charges would go up to $2.1 billion after taxes inclusive of “provisioning for settled cases and an estimate for those cases which we have received and are still outstanding.” Paxil also faced a “vast majority of product liability cases” which was settled. GSK also entered an agreement with the United States attorney’s office in Massachusetts and the Justice Department to pay $750 million to settle the investigation of its manufacturing plant in Cidra, Puerto Rico after the 2007 censures from the regulators related to quality control issues.

Dan Troy, general counsel for GSK said, “The charge we have announced today reflects the company’s ongoing efforts to resolve certain longstanding legal cases…This represents a substantial proportion of GSK’s outstanding litigation. This progress is helping us to reduce financial uncertainty and risk for shareholders.”

The annual report for 2009 at GSK has an eight page report only on the legal proceedings citing the 17 disputes over intellectual property, five lawsuits related to product liability, six to do with marketing and promotion and three each for anti-trust, wholesaling and corporate matters. These reflect the legal quagmire most pharmaceutical giants are in.

However, Jeremy Batstone-Carr, a pharmaceutical sector analyst at Charles Stanley & Company in London said that this announcement means that GSK was trying “to put the legal issues over these products into the past.”

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Glaxo announces a $2.3 billion in legal liability charges. News-Medical. Retrieved on June 17, 2024 from https://www.news-medical.net/news/20100716/Glaxo-announces-a-2423-billion-in-legal-liability-charges.aspx.

  • MLA

    Mandal, Ananya. "Glaxo announces a $2.3 billion in legal liability charges". News-Medical. 17 June 2024. <https://www.news-medical.net/news/20100716/Glaxo-announces-a-2423-billion-in-legal-liability-charges.aspx>.

  • Chicago

    Mandal, Ananya. "Glaxo announces a $2.3 billion in legal liability charges". News-Medical. https://www.news-medical.net/news/20100716/Glaxo-announces-a-2423-billion-in-legal-liability-charges.aspx. (accessed June 17, 2024).

  • Harvard

    Mandal, Ananya. 2018. Glaxo announces a $2.3 billion in legal liability charges. News-Medical, viewed 17 June 2024, https://www.news-medical.net/news/20100716/Glaxo-announces-a-2423-billion-in-legal-liability-charges.aspx.

Comments

  1. Philip Philip United States says:

    There is an interesting write-up on this at the Skeptics Health Journal Club, especially on how similar this latest debacle is to other recent recalled drugs both in the behavior of industry and of the US FDA.
    It can be found here
    healthjournalclub.blogspot.com/.../...r-again.html
    if anyone is interested.  

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative therapeutic strategies for combating type 2 diabetes